Hematologic Malignancies
credits/contact hours

Learn From the Experts About
Clinical Management of Novel Therapies for Hematologic Malignancies: Targeted Therapies, CAR-T, and Beyond

Gain insights and clinical knowledge on the science of new targeted therapies and immunotherapies for the treatment of hematologic malignancies. Learn how to manage the side effects and other clinical issues associated with these new treatments in a case-based, informal educational setting. 


Diffuse Large B-Cell Lymphoma (DLBCL)

  • Describe the current treatments for early stage DLBCL
  • Describe the current treatments for relapsed/refractory DLBCL
  • Discuss the emerging therapies, their potential adverse events and the associated clinical trials underway for DLBCL
  • Describe appropriate patient selection criteria for CAR-T therapy
  • Recall the strategies to mitigate for the potential of cytokine release syndrome and other serious side effects with CAR-T therapy

 Mantle Cell Lymphoma (MCL)

  • Describe the latest information on risk stratification of patients with MCL
  • Identify appropriate usage of new agents in the treatment of MCL
  • Describe how to best manage treatment side effects for patients with MCL

 Acute Myeloid Leukemia (AML)

  • Discuss newly approved and investigational therapies and clinical trials for AML
  • Describe mitigation strategies to manage side effects of emerging therapies in AML
  • Discuss advancements in diagnostic tests used in risk stratification for AML including next-generation sequencing (NGS) for the discovery of novel molecular abnormalities as defined by the World Health Organization (WHO) and European Leukemia Network
  • Discuss management of minimal residual disease

Chronic Lymphocytic Leukemia (CLL)

  • Recall high-risk CLL determinants including clinical factors, biologic and genetic factors, and complex karyotypes
  • Incorporate emerging therapies into treatment plans for patients with CLL, based upon an evaluation of efficacy and safety, as well as patient age, performance status and comorbidities
  • Integrate mitigation strategies into treatment planning for managing adverse events such as patient education, prophylactic measures and dose adjustments in CLL

Follicular Lymphoma

  • Describe prognostic factors and risk adaptive strategies for treatment decisions in follicular lymphoma
  • Discuss the latest data on efficacy and safety of newly approved agents for primary, relapsed, and refractory follicular lymphoma
  • Formulate strategies to manage treatment side effects for patients with follicular lymphoma
  • Recall clinical trials of novel targeted therapies for the management of newly diagnosed and relapsed/refractory follicular lymphoma

Myeloproliferative Neoplasms (MPNs)

  • Describe the latest WHO disease definitions for diagnosing myeloid malignancies
  • Discuss the normal physiology of the JAK-STAT biochemical signaling pathway, as well as its dysregulation in myeloproliferative neoplasms
  • Identify germline mutations in patients with predisposition for MPN/MDS

Multiple Myeloma

  • Evaluate safety and efficacy data of emerging therapies for the treatment of multiple myeloma
  • Formulate strategies for patient care for patients requiring maintenance therapy for relapsed/refractory multiple myeloma
  • Evaluate use of monoclonal antibodies for the treatment of multiple myeloma, particularly mechanism of action, administration and dosing, and side effect management

Hodgkin Lymphoma

  • Discuss emerging therapies for the treatment of relapsed refractory classic Hodgkin lymphoma (cHL)
  • Discuss the mechanism of action and use of PD-1 inhibitors in the treatment of cHL
  • Describe clinical trials underway in cHL
  • Discuss strategies to manage adverse events and reduce short- and long-term treatment-related toxicities of existing regimens for cHL


By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.